Teva Nabs Approval to Market Generic GSK Inhaler

Jan 30, 2017

Reuters

Teva Pharmaceutical Industries has received U.S. approval to market a copy of GlaxoSmithKline's Advair inhaler, called AirDuo RespiClick, according to a Reuters article.

Teva's version of GSK's medicine is not a direct substitute for Advair and is only approved for asthma, while Advair is also used for chronic obstructive pulmonary disease (COPD), the story said.

AirDuo offers the same two drugs as Advair--fluticasone propionate and salmeterol--but it delivers a lower dose of salmeterol. It also uses Teva's Respiclick inhaler rather than a copy of GSK's device.

Read the Reuters article